Bristol-Myers Squibb (BMS, NYSE: BMY), a leading US pharmaceutical company, has announced the clinical application of its drug azacitidine in Shenzhen, within the Guangdong Hong Kong Macao Greater Bay Area (GBA). This marks the use of the world’s first and only oral maintenance therapy for acute myeloid leukemia (AML) in the region, made possible by the “Hong Kong Macau Drug and Device Access” policy.
Azacitidine, an oral demethylation agent, offers a more convenient outpatient treatment option for patients with AML. Its oral formulation significantly reduces the adverse reactions commonly associated with traditional administration routes. The drug received marketing approval in Hong Kong in September 2023 and was included in the list of urgently needed imported drugs from Hong Kong and Macao for clinical use in the GBA at the start of 2024.
This policy has facilitated the expedited access to azacitidine for patients in the GBA, highlighting the region’s commitment to improving cancer care and providing innovative treatment options to those in need.- Flcube.com
